Table 4 Baseline features of the patients.
Trials | Mean age | Males (%) | Ht (%) | Ds (%) | Cs (%) | DM (%) |
|---|---|---|---|---|---|---|
Z/D | Z/D | Z/D | Z/D | Z/D | Z/D | |
ENDEAVOR III | 61.4/61.7 | 65.3/81.4 | 70.7/74.3 | 83.5/86.7 | 66.5/75.2 | 29.7/28.3 |
ENDEAVOR IV | 63.5/63.6 | 66.9/68.5 | 79.4/82.6 | 81.4/84.8 | 62.6/60.4 | 31.2/30.5 |
ISAR TEST 2 | 67.2/66.6 | 75.5/77.3 | 67.6/63.9 | 65.5/69.0 | 18.0/17.3 | 26.3/27.2 |
PRODIGY | 68.0/68.0 | 78.0/78.0 | 69.0/73.0 | 53.0/59.0 | 26.0/22.0 | 24.0/28.0 |
PROTECT | 62.3/62.1 | 77.0/76.0 | 65.0/63.0 | 62.0/63.0 | 25.0/25.0 | 100/100 |
SORT OUT III | 64.3/64.3 | 73.0/74.0 | 54.0/51.0 | 70.0/68.0 | 32.0/32.0 | 15.0/14.0 |
ZEST | 62.1/62.2 | 64.2/65.2 | 65.9/63.4 | 51.9/50.0 | 25.4/27.7 | 30.4/27.9 |
PRISON III | — | — | — | — | — | — |
ZOMAxx I | 63.0/63.0 | 75.0/77.0 | 69.0/67.0 | 78.0/72.0 | 24.0/19.0 | 22.0/26.0 |
RESOLUTE | 64.4/64.2 | 76.6/77.2 | 71.1/71.3 | 64.0/67.7 | 26.5/26.5 | 23.5/23.4 |
TWENTE | 63.9/64.5 | 72.5/72.6 | 55.4/55.8 | 57.0/61.4 | 25.3/23.6 | 22.7/20.6 |
TWENTE II | 63.9/63.9 | 73.4/72.6 | 55.2/53.5 | 46.1/47.5 | 23.6/25.5 | 18.4/17.3 |
